Claritev (CTEV) & Its Rivals Head to Head Survey

Claritev (NYSE:CTEV – Get Free Report) is one of 93 publicly-traded companies in the “Healthcare Technology” industry, but how does it compare to its competitors? We will compare Claritev to similar companies based on the strength of its profitability, earnings, analyst recommendations, dividends, valuation, institutional ownership and risk.

Volatility and Risk

Claritev has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Claritev’s competitors have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Claritev and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Claritev 1 2 6 0 2.56
Claritev Competitors 456 1540 2762 89 2.51

Claritev currently has a consensus price target of $44.83, indicating a potential upside of 111.38%. As a group, “Healthcare Technology” companies have a potential upside of 50.52%. Given Claritev’s stronger consensus rating and higher probable upside, research analysts clearly believe Claritev is more favorable than its competitors.

Valuation and Earnings

This table compares Claritev and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Claritev $1.02 billion -$284.28 million -1.29
Claritev Competitors $351.19 million -$24.15 million 11.80

Claritev has higher revenue, but lower earnings than its competitors. Claritev is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Claritev and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Claritev -27.05% N/A -5.74%
Claritev Competitors -749.77% -27.84% -15.02%

Institutional & Insider Ownership

87.2% of Claritev shares are held by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are held by institutional investors. 7.4% of Claritev shares are held by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Claritev beats its competitors on 8 of the 13 factors compared.

About Claritev

(Get Free Report)

Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.

Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.